Navigation Links
Scripps Research scientists find way to block stress-related cell death
Date:6/2/2011

Scientists from the Florida campus of The Scripps Research Institute have uncovered a potentially important new therapeutic target that could prevent stress-related cell death, a characteristic of neurodegenerative diseases such as Parkinson's, as well as heart attack and stroke.

In the study, published recently in the journal ACS Chemical Biology, the scientists showed they could disrupt a specific interaction of a critical enzyme that would prevent cell death without harming other important enzyme functions.

The enzyme in question is c-jun-N-terminal kinase (JNK), pronounced "junk," which has been implicated in many processes in the body's response to stresses, such as oxidative stress, protein misfolding, and metabolic disorder. JNK also plays an important role in nerve cell survival and has become a target for drugs to treat neurodegenerative disorders such as Parkinson's disease.

In recent studies, JNK has been found to migrate to the mitochondriathe part of the cell that generates chemical energy and that is involved in cell growth and death. That migration, coupled with JNK activation, is associated with a number of serious health issues, including apoptosis or programmed cell death, liver damage, neuronal cell death, stroke and heart attack.

"Activated JNK migrates to the mitochondria in reaction to a stress signal," said Philip LoGrasso, professor in the Department of Molecular Therapeutics and senior director for drug discovery at Scripps Florida who led the study. "Once there, it amplifies the effects of reactive oxygen species that cause significant damage to the cell. We developed a small peptide that intervenes in JNK migration and blocks those harmful effectsspecifically cell death."

LoGrasso noted that the team was able to block JNK mitochondrial interaction without harming any other important enzyme processes, such as JNK's impact on gene expression. These findings, LoGrasso said, suggest that this interaction could be exploited in the development of a new drug.

"The peptide we developed will never be a drug, but it is an important new investigative tool that we can use to selectively probe mitochondrial biology," he said. "Our hope is to produce a small molecule that can mimic the inhibitory effect of this peptide. If we can do that, we might be able to selectively inhibit JNK mitochondrial interaction and use it to treat a number of diseases."


'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert

Related biology news :

1. Scripps Research scientists find key mechanism in transition to alcohol dependence
2. Scripps Research scientists create new genetic model of premature aging diseases
3. Scripps Research scientists identify mechanism of long-term memory
4. Scripps Research scientists uncover new DNA role in modifying gene function
5. Scripps Research scientists find dual switch regulates fat formation
6. Common chaperone protein found to work in surprising way, say Scripps Research scientists
7. Dr. Daniel Von Hoff presented with top genomics award from Scripps
8. Scripps Research team discovers new details about medically important protein family
9. Scripps Research scientists develop new test for pluripotent stem cells
10. Scripps Research scientists create cell assembly line
11. Scripps oceanography researchers discover arctic blooms occurring earlier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2017)... 2017 NXT-ID, Inc. (NASDAQ: NXTD ) ... of its 2016 Annual Report on Form 10-K on Thursday April ... ... in the Investor Relations section of the Company,s website at ... at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
Breaking Biology News(10 mins):
(Date:9/17/2017)... , ... September 17, 2017 , ... ... the South Korean Ministry of Food and Drug Safety (KMFDS) for an Investigational ... against the Middle East Respiratory Syndrome coronavirus (MERS-CoV). The study in Korea represents ...
(Date:9/14/2017)... ... September 14, 2017 , ... ... launch of its CliniControl™ (CC) product portfolio, clinically-relevant starting and ancillary materials ... of human Mesenchymal Stem/Stromal Cell (hMSC)-based therapies. The CliniControl product portfolio will ...
(Date:9/14/2017)... ... September 14, 2017 , ... AIM Global, the worldwide standards agency for ... won the 2017 Case Study Competition for AIDC. The award is given to ... risk” and push the adoption of automated data collection systems further. The TRACTUS ...
(Date:9/12/2017)... ... September 12, 2017 , ... PhysIQ, a Chicago-based company ... ambulatory patient monitoring and clinical trial support, earned DPharm Idol 2017 honors at ... , Launched in 2005, PhysIQ leverages artificial intelligence (AI) to empower digital ...
Breaking Biology Technology: